Once-weekly amycretin, a novel peptide activating GLP-1, amylin, and calcitonin receptors, produced rapid, substantial, and ...

Amycretin, a new weight-loss treatment from Novo Nordisk, combines two hunger hormones, helping participants lose nearly ...

Amgen (NASDAQ:AMGN) announced on Monday that its new weight loss treatment, MariTide, resulted in an average weight loss of ...

An article published in the journal Nature Metabolism presents an experimental drug that stimulates adipose tissue cells to ...

CHICAGO -- An investigational injectable that only requires dosing once every 4 weeks led to substantial weight loss in ...

Amgen (NASDAQ:AMGN) today announced full results from Part 1 of the Phase 2 study of MariTide (maridebart cafraglutide, formerly AMG 133), a long-acting, peptide-antibody conjugate subcutaneously ...

In a trial, the daily GLP-1 pill showed "significant" results and similar side effects to injectable GLP-1 drugs like Ozempic ...

Amycretin helped patients lose over 24% of their weight, compared with an average of about 17% for Wegovy.

The effect of Novo Nordisk’s amycretin injections on body weight showed no signs of plateauing after 36 weeks, suggesting the ...

Many women struggle with weight loss due to emotional factors and conflicting advice. Common mistakes include drastically ...

A novel weight loss drug in the same class as semaglutide has successfully met its targets in its largest clinical trial yet, ...